These recent developments have enabled tangible clinical benefits in different solid tumor types [2–5], especially in renal cell cancer, and supported subsequent development of VEGF inhibitors, mainly tyrosine kinase inhibitors (TKI) directed against VEGF receptors (VEGFR). Here, VEGFA is linked to renal cell adenocarcinoma.